a Cancer Prognostics and Health Outcomes Unit , University of Montreal Health Center , Montreal , Canada.
b Department of Urology , SS Annunziata Hospital, "G. D'Annunzio" University of Chieti , Chieti , Italy.
Expert Rev Anticancer Ther. 2018 Apr;18(4):377-387. doi: 10.1080/14737140.2018.1439744. Epub 2018 Feb 15.
In patients with muscle invasive or Bacillus Calmette-Guérin refractory urothelial carcinoma of the urinary bladder (UCUB) radical cystectomy represents the standard of care. However, a proportion of patients experience disease progression, local recurrence and/or metastatic disease. Areas covered: This review provides an overview of available therapeutic strategies after radical cystectomy and examines ongoing clinical trials including cytotoxic chemotherapy and immunotherapy. Expert commentary: Cytotoxic chemotherapy offers limited benefit in UCUB patients. However, the recent introduction of immunotherapy provides new hope for durable responses or possibly complete cures.
在患有肌肉浸润性或卡介苗难治性膀胱尿路上皮癌（UCUB）的患者中，根治性膀胱切除术是标准治疗方法。然而，一部分患者会出现疾病进展、局部复发和/或转移性疾病。
本综述概述了根治性膀胱切除术后的现有治疗策略，并检查了正在进行的临床试验，包括细胞毒性化疗和免疫治疗。
细胞毒性化疗在 UCUB 患者中获益有限。然而，最近免疫疗法的引入为持久反应或可能的完全治愈提供了新的希望。
